Yes, subcutaneous enoxaparin (Lovenox) is absolutely appropriate and FDA-approved for NSTEMI.
Enoxaparin is specifically indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction (which includes NSTEMI), and should be given subcutaneously at 1 mg/kg every 12 hours in conjunction with aspirin. 1
Dosing and Administration
The FDA-approved regimen for NSTEMI is straightforward:
- 1 mg/kg subcutaneously every 12 hours 1
- Given concurrently with aspirin (100-325 mg daily) 1
- Continue for minimum 2 days until clinical stabilization 1
- Usual duration is 2-8 days (up to 12.5 days studied in trials) 1
Dose adjustments:
- If creatinine clearance <30 mL/min: reduce to 1 mg/kg subcutaneously every 24 hours 2, 1
- No initial IV bolus is needed for NSTEMI (unlike STEMI) 2
Guideline Support
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines explicitly include enoxaparin as initial therapy for NSTE-ACS, with the dosing table specifying "1 mg/kg subcutaneous every 12 h" as the standard regimen 2. The 2021 ESC guidelines similarly endorse enoxaparin as having "a predictable dose-effect relationship and a lower risk for heparin-induced thrombocytopenia (HIT) compared to UFH" 3.
If Proceeding to PCI
Critical timing considerations if the patient goes to the catheterization lab:
- If last subcutaneous dose was within 8 hours: no additional enoxaparin needed 2
- If last dose was 8-12 hours prior OR only 1 dose given: give 0.3 mg/kg IV 2
- If no prior anticoagulant: give 0.5-0.75 mg/kg IV bolus 2
Evidence Base
Real-world data from over 1 million ACS patients showed enoxaparin monotherapy was associated with lower ischemic complications and death in NSTEMI patients compared to UFH, with lower bleeding risk and cost savings of approximately $2,475 per patient 4. Multiple trials including ESSENCE and TIMI 11B demonstrated enoxaparin's superiority over UFH in reducing death and cardiac events in NSTEMI patients, including those undergoing PCI 5, 6, 7.
Common Pitfalls to Avoid
- Do not underdose obese patients: While clinicians tend to reduce doses in patients >150 kg, this may compromise efficacy. Use actual body weight for dosing, though be aware bleeding risk may increase 8
- Do not give IM: Enoxaparin is for subcutaneous or IV use only 1
- Watch for spinal/epidural hematomas: If neuraxial anesthesia is planned, carefully weigh risks 1
- Do not use fondaparinux if PCI is planned: It increases catheter thrombosis risk 2
The subcutaneous route is not just acceptable—it's the standard, FDA-approved route for NSTEMI treatment with enoxaparin.